MATINAS BIOPHARMA HOLDINGS, INC. Share-based Payment Arrangement, Expense
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Share-based Payment Arrangement, Expense of $1.41 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2022-11-02
- MATINAS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2022-09-30 was $1.41M, a 33.18% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2021-09-30 was $1.06M, a 111232.63% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2020-09-30 was $953.00, a 42.03% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2020-06-30 was $945.00, a 14.96% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2018 was $3.83M, a 6.56% increase from fiscal 2017.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2017 was $3.60M, a 136.80% increase from fiscal 2016.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2016 was $1.52M, a 4.59% decline from fiscal 2015.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2015 was $1.59M, a 19.35% decline from fiscal 2014.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-09-30 | $1.41M 10-Q · filed 2022-11-02 | $3.89M 10-Q · filed 2022-11-02 | |||||
| 2021-09-30 | $1.06M 10-Q · filed 2022-11-02 | $3.22M 10-Q · filed 2022-11-02 | |||||
| 2020-09-30 | $953.00 10-Q · filed 2020-11-06 | $1.90K derived: sum of 2 quarters · filed 2020-11-06 | $3.35K 10-Q · filed 2020-11-06 | ||||
| 2020-06-30 | $945.00 10-Q · filed 2020-08-10 | $2.39K 10-Q · filed 2020-08-10 | |||||
| 2020-03-31 | $1.45K 10-Q · filed 2020-05-11 | ||||||
| 2019-09-30 | $671.00 10-Q · filed 2020-11-06 | $1.49K derived: sum of 2 quarters · filed 2020-11-06 | $2.30K 10-Q · filed 2020-11-06 | $1.03M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2019-06-30 | $822.00 10-Q · filed 2020-08-10 | $1.63K 10-Q · filed 2020-08-10 | $1.03M derived: sum of 3 quarters · filed 2020-08-10 | $1.54M derived: sum of 4 quarters · filed 2020-08-10 | |||
| 2019-03-31 | $804.00 10-Q · filed 2020-05-11 | $804.00K 10-Q · filed 2019-05-13 | $1.03M derived: sum of 2 quarters · filed 2020-05-11 | $1.54M derived: sum of 3 quarters · filed 2020-05-11 | $2.09M derived: sum of 4 quarters · filed 2020-05-11 | ||
| 2018-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.53M derived: sum of 2 quarters · filed 2019-04-01 | $2.08M derived: sum of 3 quarters · filed 2019-04-01 | $3.83M 10-K · filed 2019-04-01 | |||
| 2018-09-30 | $505.00K 10-Q · filed 2018-11-09 | $1.05M derived: sum of 2 quarters · filed 2018-11-09 | $2.80M 10-Q · filed 2018-11-09 | $4.16M derived: sum of 4 quarters · filed 2019-05-13 | |||
| 2018-06-30 | $550.00K 10-Q · filed 2018-08-09 | $2.30M 10-Q · filed 2018-08-09 | $3.66M derived: sum of 3 quarters · filed 2019-05-13 | $4.21M derived: sum of 4 quarters · filed 2019-05-13 | |||
| 2018-03-31 | $1.75M 10-Q · filed 2019-05-13 | $3.11M derived: sum of 2 quarters · filed 2019-05-13 | $3.66M derived: sum of 3 quarters · filed 2019-05-13 | $3.97M derived: sum of 4 quarters · filed 2019-05-13 | |||
| 2017-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.91M derived: sum of 2 quarters · filed 2019-04-01 | $2.23M derived: sum of 3 quarters · filed 2019-04-01 | $3.60M 10-K · filed 2019-04-01 | |||
| 2017-09-30 | $551.00K 10-Q · filed 2018-11-09 | $867.00K derived: sum of 2 quarters · filed 2018-11-09 | $2.24M 10-Q · filed 2018-11-09 | $2.48M derived: sum of 4 quarters · filed 2018-11-09 | |||
| 2017-06-30 | $316.00K 10-Q · filed 2018-08-09 | $1.69M 10-Q · filed 2018-08-09 | $1.93M derived: sum of 3 quarters · filed 2018-08-09 | $2.41M derived: sum of 4 quarters · filed 2018-08-09 | |||
| 2017-03-31 | $1.37M 10-Q · filed 2018-05-09 | $1.62M derived: sum of 2 quarters · filed 2018-05-09 | $2.10M derived: sum of 3 quarters · filed 2018-05-09 | $2.50M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2016-12-31 | $245.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $725.00K derived: sum of 2 quarters · filed 2018-03-16 | $1.13M derived: sum of 3 quarters · filed 2018-03-16 | $1.52M 10-K · filed 2018-03-16 | |||
| 2016-09-30 | $480.00K 10-Q · filed 2017-11-14 | $881.00K derived: sum of 2 quarters · filed 2017-11-14 | $1.27M 10-Q · filed 2017-11-14 | $1.64M derived: sum of 4 quarters · filed 2018-03-16 | |||
| 2016-06-30 | $401.00K 10-Q · filed 2017-08-08 | $794.00K 10-Q · filed 2017-08-08 | $1.16M derived: sum of 3 quarters · filed 2018-03-16 | $1.65M derived: sum of 4 quarters · filed 2018-03-16 | |||
| 2016-03-31 | $393.00K 10-Q · filed 2017-05-15 | $757.00K derived: sum of 2 quarters · filed 2018-03-16 | $1.25M derived: sum of 3 quarters · filed 2018-03-16 | $1.65M derived: sum of 4 quarters · filed 2018-03-16 | |||
| 2015-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $858.00K derived: sum of 2 quarters · filed 2018-03-16 | $1.26M derived: sum of 3 quarters · filed 2018-03-16 | $1.59M 10-K · filed 2018-03-16 | |||
| 2015-09-30 | $494.00K 10-Q · filed 2016-11-14 | $895.00K derived: sum of 2 quarters · filed 2016-11-14 | $1.23M 10-Q · filed 2016-11-14 | $1.75M derived: sum of 4 quarters · filed 2016-11-14 | |||
| 2015-06-30 | $401.00K 10-Q · filed 2016-08-15 | $734.00K 10-Q · filed 2016-08-15 | $1.26M derived: sum of 3 quarters · filed 2016-08-15 | $2.16M derived: sum of 4 quarters · filed 2016-08-15 | |||
| 2015-03-31 | $333.00K 10-Q · filed 2016-05-13 | $860.00K derived: sum of 2 quarters · filed 2016-05-13 | $1.76M derived: sum of 3 quarters · filed 2016-05-13 | $2.03M derived: sum of 4 quarters · filed 2016-05-13 | |||
| 2014-12-31 | $527.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $1.43M derived: sum of 2 quarters · filed 2016-03-30 | $1.70M derived: sum of 3 quarters · filed 2016-03-30 | $1.97M 10-K · filed 2016-03-30 | $1.97M 10-K · filed 2015-03-31 | ||
| 2014-09-30 | $900.00K 10-Q · filed 2015-11-10 | $1.17M derived: sum of 2 quarters · filed 2015-11-10 | $1.45M 10-Q · filed 2015-11-10 | $1.60M derived: sum of 4 quarters · filed 2015-11-10 | |||
| 2014-06-30 | $274.00K 10-Q · filed 2015-08-13 | $548.00K 10-Q · filed 2015-08-13 | $315.00M 10-Q · filed 2014-08-08 | $696.00K derived: sum of 3 quarters · filed 2015-08-13 | $874.00K derived: sum of 4 quarters · filed 2015-08-13 | ||
| 2014-03-31 | $274.00K 10-Q · filed 2015-05-15 | $158.00K 10-Q · filed 2014-06-06 | $422.00K derived: sum of 2 quarters · filed 2015-05-15 | $600.00K derived: sum of 3 quarters · filed 2015-05-15 | |||
| 2013-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $326.00K derived: sum of 2 quarters · filed 2015-03-31 | $326.00K 10-K · filed 2015-03-31 | ||||
| 2013-09-30 | $178.00K 10-Q · filed 2014-11-14 | $178.00K 10-Q · filed 2014-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |